Divalproex Sodium
Product Images NDC 68151-4162

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68151-4162). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (68151 4162)

Label for Divalproex Sodium delayed release 500 mg tablet showing manufacturer as UNICHEM, lot number ZDPH15091, and expiration date 09/16. The label includes a barcode and indicates the product is Rx only. The labeler is Carilion Materials Management.*

FDA Label Image

Structure (Divalproextablets Figure 01)

Chemical structure of Divalproex Sodium, showing repeating units with distinct chemical bonds and sodium ion representation as part of the compound.*

FDA Label Image

Comparison Of Percentage Of Patient Separated By Study (Divalproextablets Figure 02)

A bar chart comparing percentages between placebo (PBO) and Divalproex Sodium (DVPX) in two studies. Study 1 (YMRS) shows 26% for PBO and 60% for DVPX, and Study 2 (MRS) shows 29% for PBO and 58% for DVPX.*

FDA Label Image

% Reduction In Cps Rate Vs % Of Patients (Divalproextablets Figure 03)

A line graph comparing the percentage reduction in CPS rate between Divalproex Sodium and placebo groups across different percentages of patients. The graph shows improvement and worsening on the vertical axis, illustrating Divalproex Sodium's performance relative to placebo.*

FDA Label Image

% Reduction In Cps Rate Vs % Of Patients (Divalproextablets Figure 04)

A line graph depicting the percentage reduction in complex partial seizures (CPS) rate against the percentage of patients for high and low doses of Divalproex Sodium. The y-axis measures improvement versus worsening in CPS rate, while the x-axis represents the percent of patients. Two curves show greater reduction in CPS rate with high dose compared to low dose.*

FDA Label Image

Mean 4-week Migraine Rates (Divalproextablets Figure 05)

A bar chart comparing results of two studies measuring an unspecified variable for Placebo and Divalproex Sodium groups. In Study 1, Placebo shows the highest value near 6, with Divalproex Sodium lower around 3.5. In Study 2, Placebo is around 4.5 while Divalproex Sodium is about 3. This chart visually contrasts Placebo versus Divalproex Sodium outcomes across the two studies.*

FDA Label Image

Company Logo (Divalproextablets Figure 06)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.